AQUINOX PHARMACEUTICALS INC

Inactive Instrument

Analyst Reco. Aquinox Pharmaceuticals Inc Nasdaq

Equities

US03842B1017

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

William Blair Initiates Neurogene With Outperform Rating	Mar. 21	MT
HC Wainwright Starts Neurogene With Buy Rating, $45 Price Target	Jan. 08	MT
Stifel Starts Coverage on Neurogene with Buy Rating, $31 Price Target	Jan. 05	MT
Mizuho Adjusts Price Target on Neoleukin Therapeutics to $1.50 From $2, Keeps Neutral Rating	23-05-09	MT
North American Morning Briefing : Stock Futures Dip as Higher Rate Fears Persist	23-03-09	DJ
Guggenheim Downgrades Neoleukin Therapeutics to Neutral From Buy	23-01-03	MT
Mizuho Downgrades Neoleukin Therapeutics to Neutral From Buy, Adjusts Price Target to $2 From $21	22-11-15	MT
Canaccord Genuity Downgrades Neoleukin Therapeutics to Hold From Buy, Adjusts Price Target to $1 From $10	22-11-15	MT
BofA Securities Downgrades Neoleukin Therapeutics to Underperform From Buy, Adjusts Price Target to $1 From $3	22-09-12	MT
HC Wainwright Adjusts Neoleukin Therapeutics' Price Target to $6 from $22, Maintains Buy Rating	22-09-12	MT
Stifel Nicolaus Adjusts Price Target for Neoleukin Therapeutics to $14 From $18, Maintains Buy Rating	22-08-10	MT
Canaccord Genuity Assumes Neoleukin Therapeutics at Buy with $10 Price Target	22-07-06	MT
Piper Sandler Adjusts Price Target on Neoleukin Therapeutics to $6 From $25, Reiterates Overweight Rating	22-05-31	MT
Guggenheim Adjusts Price Target for Neoleukin Therapeutics to $12 From $16, Maintains Buy Rating	22-05-10	MT
Piper Sandler Adjusts Neoleukin Therapeutics Price Target to $25 From $30, Maintains Overweight Rating	22-03-02	MT
NEOLEUKIN THERAPEUTICS : Piper Sandler Starts Neoleukin Therapeutics at Overweight with $30 Price Target	21-08-06	MT
NEOLEUKIN THERAPEUTICS : Stifel Starts Neoleukin Therapeutics at Buy With $18 Price Target	21-01-06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer